T2 Biosystems and Allergan have signed an agreement for the development of a novel bacterial resistance diagnostic panel that detects Gram-negative bacteria and antibiotic resistance in patients with serious bacterial infections.

Pursuant to the agreement, Allergan will pay $4m in milestone payments for the development of the new panel and for expansion of another under-development T2Bacteria panel to T2 Biosystems, which retains exclusive worldwide rights to distribute all the products developed through the partnership.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Halt Medical has received an exclusive licence to use InnerOptic Technologies' FDA-cleared Aim 3D guidance software, which will be incorporated in Halt’s Acessa Guidance System, for use in uterine fibroid ablation procedure.

The Acessa Guidance system, which incorporates electromagnetic tracking technology and radiofrequency ablation, guides physicians in reaching the targeted fibroid by providing clear picture of the device trajectory and real-time tracking of the surgical instruments.

"The new company, in which, the former will own the majority stake of 51%, will be a healthcare technology company."

Diagnostic tests manufacturer, Guangzhou Wondfo Biotech, intends to form a joint venture (JV) with an individual in Guangzhou, China.

The new company, in which, the former will own the majority stake of 51%, will be a healthcare technology company.

With a vision to develop platforms that transform cell-based biological processes to accelerate the discovery, development and delivery of therapeutics, bio-technology firm Berkeley Lights (BLI) has partnered with Hoffman-LaRoche (Roche).

The two-year collaboration focuses on innovating and automating Roche's antibody discovery technology using BLI's opto-nanofluidic systems and devices and is anticipated to increase the efficiency and speed of novel therapeutics discovery.

Pharmaceutical test appliances and automated systems developer, Sotax AG, has received independent distribution rights to Waters Corporation’s Acquity UPLC H-Class System, which will be sold to drug manufacturers and pharmaceutical laboratories in the US, Canada, the UK, France, Germany, Italy, Switzerland and the Czech Republic.

The new collaboration combines the technologies of both the companies and enables their customers to efficiently streamline their analysis, characterisation and preparation of pharmaceutical samples thus helping them to improve their productivity and profitability.